Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Dai-Ichi Karkare Limited (DIKL) was set up in 1960 as a private limited company for the manufacture of speciality chemicals. The Company entered into technical collaboration with the ...

Following its demutualization and IPO in 2010, Daiichi Life Group has transformed from one of Japan’s big four traditional life insurers to a multinational holding company with a multibrand ...

Ichi the Witch is currently one of the biggest trending manga series in Weekly Shonen Jump. The series has only released 22 chapters so far and is already loved among fans. Ichi has come a long ...

The drug will be marketed under the brand name Romvimza. With its regulatory win, Ono will now go toe-to-toe with fellow Japanese pharma Daiichi Sankyo in the tenosynovial giant cell tumor (TGCT) ...

TGCT is a rare, non-cancerous tumour affecting the joints, tendons, or joint tissue. Credit: Kinga Krzeminska via Getty Images. Ono Pharmaceutical has secured approval from the US Food and Drug ...

Dai (DAI) is a widely adopted decentralized stablecoin designed to maintain a 1:1 peg with the U.S. dollar. Unlike traditional stablecoins, DAI is backed by collateralized assets and operates on the ...

HONG KONG--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of A+ (Superior) and the Long-Term Issuer Credit Rating of “aa-” (Superior) of The Dai-ichi Life Insurance ...

Ichi the Witch first made its debut with Shonen Jump last Fall, and the story has introduced fans to the titular Ichi, who is the only male witch in history. The first arcs of the series have been ...

PETALING JAYA: The tussle between IHH Healthcare Bhd, Asia’s biggest private healthcare provider, and Daiichi Sankyo Co Ltd, a pharmaceutical firm, over IHH’s open offer for the 26% of shares ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will transition from ...